We found evidence for post-treatment MMR protein deficiency and MMR gene mutation in two cases, following on this well-established phenomenon in adult patients with IDH-mutant gliomas and IDH-wildtype glioblastoma [15, 16]. The gene discussed is MRC1; the disease is glioblastoma.